

31st July, 2023

To,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

Dear Sir,

Sub: Outcome of the Board Meeting
BSE Code: 531210

The Meeting of Board of Directors was held on Monday, 31st July, 2023 at 03:30 p.m. The Board of Directors discussed and/or approved the following:

1. The Board considered and approved Un-Audited Financial Results for the quarter ended 30th June, 2023 as per Regulation 33 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In this regard, the Statutory Auditors (Independent Auditors) have carried out "Limited Review" of the above results.
Please find enclosed copy of unaudited financial results along with Limited Review Report for the quarter ended 30th June, 2023.
2. The Board approved Director's Report for the year ended 31st March, 2023.
3. The Board also approved Management Discussion Report, Corporate Governance Report, CEO's certification & other documents for the year ended 31st March, 2023.
4. The Board took note of Secretarial Audit Report (without any Qualification) issued by M/s. Sanjay Dholakia & Associates, Practising Company Secretaries for the year ended 31st March, 2023.
5. The Board discussed and finalized the date, time and mode of 37th Annual General Meeting of the Company on **Friday, 29th September, 2023, at 2.30 P. M.** through video conference or other audio-visuals means and also approved the draft notice of forthcoming Annual General Meeting of the Company.
6. The Board also approved and finalized that the Register of Members will remain closed for the purpose of **37th Annual General Meeting** of the Company from **22nd September, 2023, to 29th September, 2023** (both days inclusive). Notice relating to Book Closure will be sent shortly.

Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006



7. Further pursuant to Rule 20(4)(vii) of the Companies (Management and Administration) Rules, 2014, the Company has fixed **22nd September, 2023** as the **Cut-Off date** for the purpose of determining the eligible shareholders (holding shares either in physical form or in dematerialized form) to cast their votes electronically between **26th September, 2023** (9:30 A.M. IST) to **28th September, 2023** (5:00 P.M. IST).
8. **The Board also considered and approved appointment of M/s. Sanjay Dholakia & Associates, Practising Company Secretaries as the Secretarial Auditor for the financial year ended 31st March, 2024.**
9. The Board also discussed about the damage to the roof of the loading & unloading bay and on terrace of first floor of company's factory at Sinnar caused due to heavy rains and consequent urgent need to repair the same. It was also brought to the notice of the board that the factory premises and machinery are already 25 years old and hence there is a need for a big overhaul if it intends to get a WHO GMP certification to enter export markets globally in near future. The Board discussed about the various options including-
- a. modernisation of existing factory premises and procuring new and modern machinery. OR
 - b. Construction of new factory premises at some other place and procuring modern machinery. The existing factory premises may be sold on 'as is where is basis;
- The Board then decided to ascertain cost comparison of both the options and authorised Dr. Mani L.S. and Mr. N.K. Menon, Directors of the Company in this regard and also identify prospective buyers for existing factory and negotiate for the best price and present their analysis before the Board in order to ensure proper informed decision by the Board. Dr. Mani L S and Mr. N K Menon, Directors of the Company was also authorised to obtain a valuation report for an approved valuer for the existing factory.

The Board Meeting commenced at 3:30 p.m. and concluded at 5.30 p.m.

This is for your information and record.

Thanking you,
Yours faithfully,

FOR COLINZ LABORATORIES LTD

MR. N. K. MENON
Whole Time Director & CEO
DIN : 01111297



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006



VORA & ASSOCIATES
CHARTERED ACCOUNTANTS

101-103, REWA CHAMBERS
31, NEW MARINE LINES
MUMBAI - 400 020. INDIA

91-99305 75933
022-2200 5933 - 2200 5934
www.cavoras.com
office@cavoras.com
cavoras@gmail.com

Independent Auditor's Review Report on Unaudited Quarterly Financial Results

To
The Board of Directors,
COLINZ LABORATORIES LIMITED.

We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **COLINZ LABORATORIES LIMITED** ('the Company') for the quarter ended 30th June, 2023 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34') prescribed u/s 133 of the Companies Act, 2013 ('the Act'), SEBI Circular CIR/CF/FAC/62/2016 dated 05/07/2016 (hereinafter referred to as the 'the SEBI Circular') and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Statements Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Act read with relevant Rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VORA & ASSOCIATES
CHARTERED ACCOUNTANTS
(ICAI Firm Reg. No.: 111612W)


RONAK A. RAMBHIA
PARTNER

(Membership No.: 140371)

UDIN: 22140371BGQVVE3607
PLACE: MUMBAI
DATED: July 31, 2023

COLINZ LABORATORIES LIMITED.

(CIN NO : L24200MH1986PLC041128)

A-101, Pratik Industrial Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2023

"(Rs. In Lakhs)"

S. No.	Particulars	Un-Audited		Audited	Audited
		Quarter ended		Year Ended	
		30-Jun-23	30-Jun-22	31-Mar-23	31-Mar-23
PART -I					
1	(a)Revenue from Operation	189.94	183.81	172.07	715.49
3	(b) Other Income	4.43	4.12	4.27	17.21
3	Total Income from Operation	194.37	187.93	176.34	732.70
4	Expenses				
	(a) Cost Of Material Consumed	17.24	18.41	3.38	61.78
	(b) Purchase of Stock in Trade	36.63	53.43	45.29	170.85
	(c) Change in Inventories Of Finished Goods and Work in Progress and Stock in Trade	6.10	(14.78)	8.12	(3.32)
	(d) Employee Benefit Expenses	78.97	78.74	71.16	303.43
	(e) Finance Cost	0.81	1.23	1.30	5.23
	(f) Depreciation & Amortisation Expenses	3.26	3.22	3.23	12.89
	(g) Other Expenses	35.99	33.40	28.08	121.86
	Total Expenses	179.00	173.65	160.56	672.72
5	Profit /(Loss) Before exceptional items and tax (3-4)	15.37	14.28	15.78	59.98
6	Exceptional items	-	-	-	-
7	Profit /(Loss) before tax (5-6)	15.37	14.28	15.78	59.98
8	Tax Expenses (Provision for Taxation) Current tax				
	i) Current Tax	3.25	3.25	4.55	15.80
	ii) Deffered Tax	-	-	-	-
	iii) Tax for earlier years	-	-	(1.56)	(1.56)
	iv) MAT Credit of Earlier years	-	-	-	-
9	Profit /(Loss) for the period from continuing operations(7-8)	12.12	11.03	12.79	45.74
10	Profit /(Loss) for the period	12.12	11.03	12.79	45.74
11	Other Comprehensive Income (Net of Tax)				
	A) Item that will not be reclassified to Profit or Loss Account				
	i) Change in fair value of investment in Equity Instruments	11.40	(6.05)	(2.81)	(0.57)
12	Total Comprehensive Income for the period (10+11) Comprising	23.52	4.98	9.98	45.17
13	Earning per equity share (for Continuing operation) (In Rs.)				
	i) Basic	0.48	0.44	0.51	1.82
	ii) Diluted	0.48	0.44	0.51	1.82

Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006

NOTES TO THE FINANCIAL RESULTS :-

- 1) The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 31st July, 2023.
- 2) The above results of the Company has been audited by the Statutory Auditors and they have issued an unqualified audit opinion on the same.
- 3) The Company is primarily engaged in the business of manufacturing Pharmaceutical Formulations and there is no other reportable segment.
- 4) Previous period figures have been regrouped/ rearranged / reclassified, wherever necessary.
- 5) In accordance with regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulation,2015, The Un-Audited Results for Quarter and period ended 30th June,2023 are available on the BSE website (URL: www.bselindia.com) and the Company's website (URL: www.findoc-cll.in).

Place : Mumbai
Date : 31-07-2023

Narayan
an Kutty
Menon

Digitally signed by Narayanan
Kutty Menon
DN: c=IN, o=Personal,
2.5.4.20=e144bf8a71522c4aa75e2
3a2fd752058a77f7ce27bbc39d7059
17321fb1bea5d6,
postalCode=400081,
st=Maharashtra,
serialNumber=a9805117acb4e43f
b5414c7533bf7ab2f4c2488011804
73a0b7bce8cbde87e36,
cn=Narayanan Kutty Menon
Date: 2023.08.09 18:04:20 +05'30'

For and on behalf of the Board
COLINZ LABORATORIES LTD.
CIN NO : L24200MH1986PLC041128

Dr. MANI L. S.
(Director)
(DIN NO : 00825886)



(WTD & CEO)

Colinz Laboratories Limited
CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006